Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline

AssureMDx shows strong clinical promise, but Medicare coverage remains a 2028 target.

What the company is saying

Photocure ASA is highlighting progress on the commercial and reimbursement strategy for AssureMDx since acquiring Vesica Health in June 2026. The company emphasizes encouraging discussions with pricing authorities, suggesting potential reimbursement above initial expectations, but provides no specific figures. They stress the FDA Breakthrough Device Designation received in February 2026 and the inclusion of AssureMDx in the 2025 AUA/SUFU microhematuria guidelines as key validation milestones. Photocure acknowledges that AssureMDx was not included in the November 2026 Novitas LCD for urine-based biomarkers, meaning Medicare coverage is still expected in 2028, consistent with prior planning. The company points to substantial published clinical evidence, including a large prospective study showing 89% of microhematuria patients could avoid cystoscopy and all upper-tract urothelial cancers were detected. CEO Dan Schneider frames the narrative as one of regulatory and clinical progress, with ongoing and planned studies (SeARCH in the Netherlands, PATHWAY in the US) aimed at generating further evidence for future Medicare coverage. The tone is confident, focusing on milestones achieved and next steps toward market access.

What the data suggests

The disclosed data confirm AssureMDx's strong clinical performance, with 96% sensitivity, negative predictive value above 99%, and an area under the curve of 0.96 for bladder cancer detection. In the largest prospective study, the test could spare 89% of microhematuria patients from cystoscopy while detecting all upper-tract urothelial cancers. The SeARCH study in the Netherlands is enrolling around 1,100 patients and is supported by a Dutch Cancer Society grant, while the PATHWAY study in the US is in protocol finalization. Bladder cancer remains a major health burden, with 1,978,000 prevalent cases, 635,000 new cases, and over 227,000 deaths in 2024; 75% of cases occur in men, with recurrence rates up to 61% in year one and 78% over five years. Despite these operational and clinical milestones, no revenue, profit, or cash flow figures are disclosed, and the expectation of initial AssureMDx revenue in 2027 is still a projection. The claim of higher-than-expected reimbursement is not quantified. The LCD process has not accelerated Medicare coverage, which remains a 2028 goal pending further evidence.

Analysis

The announcement is upbeat, emphasizing regulatory progress, clinical validation, and anticipated commercial milestones for AssureMDx. While several realized achievements are disclosed—such as FDA Breakthrough Device Designation, inclusion in clinical guidelines, and strong clinical performance metrics—key commercial outcomes (Medicare pricing, coverage, and revenue) remain forward-looking and contingent on future events. The claim of 'potential reimbursement level meaningfully above assumptions' is not supported by specific figures, and the expectation of initial revenue in 2027 is still a projection. No profitability, revenue, or cash flow data is disclosed, so the true_signal cannot exceed weak_positive. The hype level is moderate, as the narrative leans on future potential and regulatory optimism, but is anchored by some concrete milestones and ongoing clinical studies. There is no evidence of a large capital outlay with uncertain returns; the only capital signal is a grant for a clinical study, not a major spend.

Risk flags

• ●Medicare coverage for AssureMDx is not expected until 2028, and the November 2026 LCD did not include the test, highlighting regulatory risk and the need for additional clinical evidence before coverage can be reconsidered.
• ●The company projects initial revenue in 2027, but this is contingent on successful reimbursement negotiations and commercial uptake, both of which remain uncertain until CMS and payer decisions are finalized.
• ●Claims of potential reimbursement above initial assumptions are not supported by disclosed figures, introducing uncertainty about the magnitude of any financial upside and the reliability of management's expectations.
• ●Ongoing and planned clinical studies (SeARCH and PATHWAY) are critical to future coverage and commercial success, but study timelines, enrollment, and outcomes could face delays or yield less favorable results than anticipated.
• ●No current financial data (revenue, profit, cash flow) is provided for Photocure or AssureMDx, limiting visibility into the company's financial health and ability to fund ongoing development if reimbursement or adoption is delayed.

Bottom line

Photocure ASA's update demonstrates that AssureMDx has robust clinical validation, regulatory momentum with FDA Breakthrough Device Designation, and inclusion in major clinical guidelines. However, the path to Medicare coverage remains protracted, with the earliest possible coverage in 2028 and no acceleration from the recent LCD process. The company expects initial revenue in 2027, but this is not guaranteed and depends on successful reimbursement and commercial adoption. While clinical performance metrics are impressive, the lack of disclosed financial data and the absence of near-term Medicare coverage mean investors should view commercial projections with caution. The most important takeaway is that while AssureMDx is clinically validated and progressing through regulatory channels, material revenue and broad reimbursement are still at least a year away and subject to execution risk. The next key catalyst will be the CMS pricing decision before year-end 2026, but full commercial realization will require further evidence and regulatory approvals.

Announcement summary

(OSE: PHO) Photocure ASA provided an update on AssureMDx™ and progress since acquiring Vesica Health on June 4, 2026. Since the acquisition, Photocure has advanced the commercial and reimbursement strategy for AssureMDx, with discussions with pricing authorities indicating a potential reimbursement level above initial acquisition assumptions. AssureMDx received FDA Breakthrough Device Designation in February 2026. Medicare pricing and coverage are on separate timelines, with CMS expected to make a final pricing determination before year-end 2026, effective January 1, 2027. The company's planning assumption at acquisition was for Medicare coverage in 2028, following submission of additional clinical evidence. The proposed Local Coverage Determination (LCD) from Novitas in May 2026 offered a chance for earlier coverage, but AssureMDx was not included in the LCD published November 6, 2026, for urine-based biomarkers in microhematuria patients. The LCD identifies additional clinical evidence required for future coverage reconsideration, so the anticipated Medicare coverage timeline remains as originally assumed. AssureMDx is supported by substantial published clinical validation evidence, including prospective studies and microhematuria-specific analyses. Novitas acknowledged the favorable diagnostic performance and potential clinical utility of the existing evidence. In the largest prospective study, AssureMDx demonstrated the potential to spare 89% of patients with microhematuria from cystoscopy, while all upper-tract urothelial cancers in the study were detected. This evidence contributed to the inclusion of AssureMDx in the 2025 microhematuria guidelines issued by the American Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/SUFU). Further clinical evidence generation is underway. The SeARCH study, an investigator-initiated randomized controlled trial conducted by Erasmus University Medical Center (Erasmus MC) in the Netherlands, involves approximately 1,100 patients with microhematuria and was initiated before Photocure's acquisition of Vesica Health. Photocure supports SeARCH as an industry sponsor and collaborator through Vesica Health, with the study supported by a grant from the Dutch Cancer Society. SeARCH is evaluating the clinical utility of AssureMDx in guiding diagnostic decisions and reducing unnecessary cystoscopies while maintaining patient safety. In parallel, Photocure is finalizing the protocol for PATHWAY, a U.S. randomized controlled clinical utility study in the intended-use microhematuria population. Photocure intends to reengage with the Novitas medical review team to discuss evidence expectations, share its clinical development approach, and seek feedback ahead of study initiation. SeARCH and PATHWAY are designed to generate high-quality randomized clinical utility evidence to support future Medicare coverage reconsideration and potential updates to clinical guidelines. The published LCD does not preclude commercialization of AssureMDx through commercial payer and other reimbursement channels, which Photocure will continue to pursue. The company continues to expect initial AssureMDx revenue in 2027, consistent with original acquisition assumptions. Dan Schneider is President and CEO of Photocure ASA. Priyam Shah is Vice President Investor Relations. Geir Bjørlo is responsible for Corporate Communications (Norway). AssureMDx is a non-invasive, urine-based molecular test for early detection of bladder cancer in patients with hematuria, validated in multiple prospective multicenter clinical studies. The test demonstrated overall sensitivity of 96%, negative predictive value (NPV) of >99%, and an area under the curve (AUC) of 0.96 for bladder cancer. Bladder cancer is the 6th most common cancer worldwide, with 1,978,000 prevalent cases (5-year prevalence rate), 635,000 new cases, and more than 227,000 deaths in 2024. Approximately 75% of all bladder cancer cases occur in men. The recurrence rate is up to 61% in year one and up to 78% over five years. NMIBC accounts for 75% of all bladder cancer cases. Photocure ASA is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO).

Disagree with this article?